Figure 1. PFS and OS in patients with PMBCL treated with axi-cel.
(A) PFS in patients with PMBCL treated with axi-cel. (B) OS in patients with PMBCL treated with axi-cel. (C) PFS among patients who received no checkpoint blockade or checkpoint blockade prior to axi-cel. (D) OS among patients who received no checkpoint blockade or checkpoint blockade prior to axi-cel .

(A) PFS in patients with PMBCL treated with axi-cel. (B) OS in patients with PMBCL treated with axi-cel. (C) PFS among patients who received no checkpoint blockade or checkpoint blockade prior to axi-cel. (D) OS among patients who received no checkpoint blockade or checkpoint blockade prior to axi-cel .

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal